Treatment of Cutaneous Leishmaniasis lesion caused by Leishmania major Using Leech Therapy in BALB/c Mice.
Research article published in Journal of vector borne diseases (2024)
Abstract
BACKGROUND OBJECTIVES: Amphotericin B, Allopurinol, Glucantime and Beta-Glucan are the main drugs currently used for the treatment of cutaneous leishmaniasis. In present study, we evaluated the effect of medical leeches on BALB/c mice models infected with Leishmania parasites. METHODS: To create animal models of leishmaniasis, BALB/c mice were inoculated with the standard Leishmania major strain MRHO / IR / 75 / ER. Treatment was performed through blood sampling with leeches. We used medical leech (Hirudo medicinalis) species. This leech is a European medicinal leech, one of several species known used as medicinal leech. 22 mice infected with Leishmania major were used for the tests .The studied mice were divided into two groups which were named with the letters L and D. The duration of blood sampling was 25 min for initial treatment, 20 min for the 2nd blood sampling and 15 min for the third times and onwards. Meglumine antimoniate (Glucantime) is a pentavalent antimony (SbV) that recommended by the World Health Organization as a golden standard treatment for all kind of leishmaniasis, but many side effects are still reported. Criteria for anti-leshmania assessment of Leech were including: Leech saliva has an anti-leishmania effect by acting on the purin pathway. Leech saliva prevents the growth and multiplication of Leishmania by a mechanism of action similar to Glucantim (breaking ATP). RESULTS: The duration of leech treatment in BALB/c mice infected with L.major parasites was about 6-8 weeks. Out of the 22 leishmaniasis mice models that underwent treatment, 13 survived until the end of the treatment duration. The recovery rate was about 56%; lesions improved in five out of the 13 surviving mice models. Paired t-test showed a significant difference between the mean wound size at the beginning of treatment and the 8th week of treatment (PV <0.0001). INTERPRETATION CONCLUSION: Considering the fact that the standard drugs for the treatment of leishmaniasis have many side effects, alternative therapies such as leech therapy can be effectively used to treat these chronic wounds. There are about 20 active substances in leech saliva. These substances include antistasin, eglins, guamerin, hirudin, saratin, bdellins, complement, and carboxypeptidase inhibitors. Leech saliva is an anticoagulant, anti-inflammation and prevents the platelet. Leech therapy was effective in treating leishmaniasis wounds in BALB/c mice. In this study, there was complete wound healing in 56% of the mice models.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Amphotericin B, Allopurinol, Glucantime and Beta-Glucan are the main drugs currently used for the treatment of cutaneous leishmaniasis. In present study, we evaluated the effect of medical leeches on BALB/c mice models infected with Leishmania parasites.
Warum dies für die Hirudotherapie relevant ist
Diese Studie evaluierte die Wirksamkeit des medizinischen Blutegels (Hirudo medicinalis) bei der Behandlung kutaner Leishmaniasis-Läsionen, verursacht durch Leishmania major, in BALB/c-Mäusen. Die Forscher fanden heraus, dass die Blutegeltherapie zu einer Heilungsrate von 56 % bei den überlebenden Mäusen führte, und stellten die Hypothese auf, dass der Blutegelspeichel eine anti-leishmaniale Wirkung ausübt, indem er auf den Purin-Stoffwechselweg einwirkt und ATP spaltet, ähnlich wie Standardbehandlungen. Diese Forschung ist unmittelbar relevant für den ASH-Bereich, da sie eine alternative therapeutische Anwendung des Blutegelsekretoms untersucht und die gerinnungshemmenden und entzündungshemmenden Eigenschaften des Speichels hervorhebt. Die Ergebnisse sind jedoch durch eine kleine Stichprobengröße und die präklinische Natur der Studie limitiert, da es sich strikt um ein Tiermodellexperiment mit hoher Mortalität handelt.
Zitation
Treatment of Cutaneous Leishmaniasis lesion caused by Leishmania major Using Leech Therapy in BALB/c Mice.
Shirani-Bidabadi · Journal of vector borne diseases, 2024
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026